Misonix Incorporated Receives FDA 510(k) Clearance For Laparoscopic HIFU Product

FARMINGDALE, N.Y., Jan. 30 /PRNewswire-FirstCall/ -- Misonix, Inc. , a developer of ultrasonic medical device technology for the treatment of cancer and other health conditions, today announced that the Food and Drug Administration (“FDA”) has granted 510(k) clearance for Misonix to market and sell the Sonatherm 600 Ultrasonic Lesion Generating System in the U.S. for ablation of certain soft tissue lesions in General Surgery procedures.

The Sonatherm 600 Ultrasonic Lesion Generating System is based on the Company’s High Intensity Focused Ultrasound (“HIFU”) technology licensed from Focus Surgery. Treatment entails placing the Sonatherm 600 transducer on the surface of the organ to be treated and engaging the HIFU energy. The concentrated acoustic waves quickly ablate the targeted tissue without puncturing or cutting the organ itself. The treatment may be performed in either laparoscopic or intraoperative procedures.

Michael A. McManus, Jr., President and CEO of Misonix, stated, “We are excited by the news from the FDA. This result is an important milestone for our HIFU technology. We believe this technology will be used to the benefit of a large surgical marketplace and related healthcare constituents that are constantly looking for innovative therapies.

“This milestone provides further validation of our strategic investments in developing our platform technologies. We have carefully selected opportunities that have significant growth potential and can also be delivered to the market in efficient and fast development timeframes. For our shareholders, that means seeing our ultrasound therapeutic products in the market in the near term. Medical devices with market potential which are similar to that of our product pipeline would typically take approximately $5 million and five years each to bring to market. We are demonstrating the ability to significantly reduce the “time to market” for our products. We expect the Sonatherm 600 to be launched in markets outside the United States (“U.S.”) sooner than in the U.S. where it will be ready for market in the 2007/2008 timeframe.

“We will continue to invest in our already cleared products for wound debridement and bone cutting. These investments will enable us to bring these products to market in the short-term and represent substantial benefit to our shareholders.

“We are proud of the progress we are making in building out our present platform in laparoscopic surgery, neurosurgery, cosmetic surgery and the development of diagnostic products. We will continue this record of growth into the development of our European market for the Sonoblate 500(R) for the treatment of prostate cancer and our new products in the treatment of kidney tissue, wound debridement and bone cutting. The true indicator of the success of our growth strategy is that each of these new products is in a market segment considerably larger than any of the present markets that we sell into.

“We believe our near term growth opportunities are real and represent significant, valuable opportunities for our shareholders. We will discuss in more detail the opportunities during our second quarter fiscal 2006 conference call in February.”

About Misonix

Misonix develops, manufactures, and markets medical, scientific, and industrial ultrasonic and air pollution systems. Misonix’s ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc. which uses high intensity focused ultrasound (“HIFU”) technology to destroy deep-seated cancerous tissues without affecting surrounding healthy tissue. Addressing a combined market estimated to be in excess of $3 billion annually, Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at http://www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. In particular, the Company may not be successful in its efforts with respect to strategic opportunities for its Laboratory and Scientific Division and the affect this activity may have on the other businesses within the Company. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, uncertainties as a result of research and development, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K.

Misonix Contact: Investor Relations Contact: Richard Zaremba Jordan M. Darrow Chief Financial Officer Darrow Associates, Inc. 631-694-9555 631-367-1866 invest@misonix.comjdarrow@optonline.net

Misonix, Inc.

CONTACT: Richard Zaremba, Chief Financial Officer of Misonix,+1-631-694-9555, invest@misonix.com; or Investor Relations: Jordan M.Darrow of Darrow Associates, Inc., +1-631-367-1866, jdarrow@optonline.net

MORE ON THIS TOPIC